At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 731 enrolled
Drug / intervention
dulaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)
In Brief
A Phase 3 clinical trial evaluating dulaglutide and IBI362 for Type 2 Diabetes. Completed, enrolled 731 participants across 1 site.
Detailed Summary
This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedNov 2022
Enrollment StartJan 2023
Primary CompletionJan 2024
Study CompletionApr 2024
TodayJul 2026
First PostedNov 7, 2022
Enrollment StartJan 6, 2023
Primary CompletionJan 26, 2024
Study CompletionApr 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.7 years ago
Interventions
dulaglutidedrug
Dulaglutide administered subcutaneously (SC) once a week.
IBI362drug
IBI362 administered subcutaneously (SC) once a week.